KidneyDAO
Verified Creator
KidneyDAO is a community-owned network funding groundbreaking research to advance kidney health, improve kidney care access...
https://kidneydao.com/
0 Following
0 Followers
0 Liked
0 Shared
Posts
Imagine a network of independent clinics, each with a DAO wallet.
Each one running AI-driven CKD risk screens using KidneyDAO tools.
Each feeding back anonymized data into the commons.
That’s the DeIPA x KidneyDAO future. 💡
Each one running AI-driven CKD risk screens using KidneyDAO tools.
Each feeding back anonymized data into the commons.
That’s the DeIPA x KidneyDAO future. 💡
Most R&D stops at publication.
KidneyDAO’s model is different: We want our work in clinics.
DeIPAs ensure CKD research doesn’t stay locked in PDFs.
They help us operationalize it. #RealWorldImpact
KidneyDAO’s model is different: We want our work in clinics.
DeIPAs ensure CKD research doesn’t stay locked in PDFs.
They help us operationalize it. #RealWorldImpact
Stem cell therapies?
KLF15 agonists?
AI-driven diagnostics?
KidneyDAO is building the pipelines.
DeIPAs are the proving grounds.
This collaboration compresses development cycles and puts patients first. ⚡
KLF15 agonists?
AI-driven diagnostics?
KidneyDAO is building the pipelines.
DeIPAs are the proving grounds.
This collaboration compresses development cycles and puts patients first. ⚡
KidneyDAO builds on-chain infrastructure for early-stage R&D.
DeIPAs build off-chain infrastructure for real-world testing and care delivery.
Together, we form a full-stack platform for CKD innovation, from bench to bedside. #DeSci #DeIPA
DeIPAs build off-chain infrastructure for real-world testing and care delivery.
Together, we form a full-stack platform for CKD innovation, from bench to bedside. #DeSci #DeIPA
DeIPAs aren’t just consumers of KidneyDAO innovations—they’re validators.
Our biomarkers live or die on clinical utility.
Who better than decentralized physician groups to trial, validate, and scale them?
Our biomarkers live or die on clinical utility.
Who better than decentralized physician groups to trial, validate, and scale them?
DeIPAs get early access to KidneyDAO’s biomarkers and therapies.
In return, their real-world feedback fuels rapid iteration and better patient outcomes.
Together, we close the loop between research and practice.
This is decentralized translational medicine in action. 🧬
In return, their real-world feedback fuels rapid iteration and better patient outcomes.
Together, we close the loop between research and practice.
This is decentralized translational medicine in action. 🧬
KidneyDAO is working on cutting-edge CKD biomarkers and therapies like KLF15 agonists.
What if frontline physicians could shape these tools?
Enter DeIPAs—decentralized physician networks that help us co-develop, test, and improve CKD care.
A new research-to-bedside pipeline!!
What if frontline physicians could shape these tools?
Enter DeIPAs—decentralized physician networks that help us co-develop, test, and improve CKD care.
A new research-to-bedside pipeline!!
Which DeSci-powered innovation will have the biggest impact on kidney disease in the next 5 years?
🧬 AI-driven biomarker discovery
🧪 Open-access clinical trials
🤖 RPM & predictive diagnostics
🧫 Organ-on-Chip therapies
Vote & tell us why! 👇
🧬 AI-driven biomarker discovery
🧪 Open-access clinical trials
🤖 RPM & predictive diagnostics
🧫 Organ-on-Chip therapies
Vote & tell us why! 👇
Over the next few days, we’ll explore a powerful concept reshaping decentralized medicine: DeIPAs (Decentralized Independent Physician Associations). 🩺🌐
What are they?
Why do they matter?
How will KidneyDAO work with them?
Let’s dive into the future of physician-led DeSci. 👇
What are they?
Why do they matter?
How will KidneyDAO work with them?
Let’s dive into the future of physician-led DeSci. 👇
Login to explore more contents